Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

§
Marginalia
Code · CFR · Title 21 — Food and Drugs · Part 312 — Investigational New Drug Application · § 312.320

§ 312.320. Treatment IND or treatment protocol.

290 words·~1 min read·/us/cfr/t21/s§ 312.320·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

Under this section, FDA may permit an investigational drug to be used for widespread treatment use.
(a)Criteria. The criteria in § 312.305(a) must be met, and FDA must determine that:
(1)Trial status.
(i)The drug is being investigated in a controlled clinical trial under an IND designed to support a marketing application for the expanded access use, or
(ii)All clinical trials of the drug have been completed; and
(2)Marketing status. The sponsor is actively pursuing marketing approval of the drug for the expanded access use with due diligence; and
(3)Evidence.
(i)When the expanded access use is for a serious disease or condition, there is sufficient clinical evidence of safety and effectiveness to support the expanded access use. Such evidence would ordinarily consist of data from phase 3 trials, but could consist of compelling data from completed phase 2 trials; or
(ii)When the expanded access use is for an immediately life-threatening disease or condition, the available scientific evidence, taken as a whole, provides a reasonable basis to conclude that the investigational drug may be effective for the expanded access use and would not expose patients to an unreasonable and significant risk of illness or injury. This evidence would ordinarily consist of clinical data from phase 3 or phase 2 trials, but could be based on more preliminary clinical evidence.
(b)Submission. The expanded access submission must include information adequate to satisfy FDA that the criteria in § 312.305(a) and paragraph
(a)of this section have been met. The expanded access submission must meet the requirements of § 312.305(b).
(c)Safeguard. The sponsor is responsible for monitoring the treatment protocol to ensure that licensed physicians comply with the protocol and the regulations applicable to investigators.
Connections11 cite this
Citation graph
cites case law
§ 312.320
Treatment IND or treatment protocol.
Fed. Reg.×11
Cites 0Cited by 11 across 1 source
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.